Patients with endometrioid carcinoma (endometrial cancer) may have a treatment choice that could spare fertility. According to researchers from the Fudan University Shanghai Cancer Centre, treating patients with megestrol acetate could spare fertility, but recurrence rates must be monitored closely.

Twelve atypical hyperplasia patients and 14 endometrioid carcinoma patients were enrolled in the study. All patients received 160 mg of megestrol acetate daily for a minimum of 12 weeks. Researchers noted response rates, recurrence rates and pregnancy rates among study participants.

About 80% of the patients responded to the megestrol acetate treatment. The average time to response was 12 weeks. At follow-up, 32 months median time, six study patients reported recurrence. Patients with PCOS or infertility were more likely to suffer recurrence. Eight study participants attempted to conceive after treatment. Two were successful resulting in one live birth.

Source: Shan BE, Ren YL, Sun JM, Tu XY, Jiang ZX, Ju XZ, Zang RY, Wang HY. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet. 2013 May 5.